An experimental drug, LX211 (LUVENIQ™; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject [...]

EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono’s proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets [...]

Prevention is receiving more attention nationwide as a successful strategy to improve the quality and lower the cost of health care. According to the Center for Disease Control and Prevention, care for chronic conditions such as obesity, diabetes, and heart disease account for 75 percent of medical care costs in the United States. Independence Blue [...]

Research co-led by an academic at the University of Hertfordshire, concludes that Cognitive Behavioural Therapy (CBT) is of no value in schizophrenia and has limited effect on depression. Professor Keith Laws, at the University’s School of Psychology, is one of the lead authors on a paper entitled: Cognitive behavioural therapy for major psychiatric disorder: does [...]

Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented at PReS 2009, a joint congress with the 2009 Congress of the European [...]